Cytokinetics CFO sells 3,134 shares post-exercise

CYTOKINETICS INC EVP and CFO Sung Lee reported a mix of option exercises and share sales.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC EVP and CFO Sung Lee reported a mix of option exercises and share sales. On June 29, 2026, Lee exercised options to acquire a total of 3,134 shares of common stock through multiple transactions at exercise prices of $44.36 and $48.51 per share. On the same date, Lee executed an open-market sale of 3,134 shares of common stock at $85.00 per share, effectively converting option-based compensation into cash while shifting exposure from options into owned shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,134 shares ($123K approx. pre-tax spread)

Exercise and Sale 11 txns

Insider Lee Sung

Role EVP, Chief Financial Officer

Sold 3,134 shs ($266K)

Approx. gross sale proceeds $266K

Approx. exercise cost $144K

Approx. pre-tax spread $123K

Type	Security	Shares	Price	Value
Exercise	Incentive Stock Option (Right to Buy)	188	$0.00	$0.00
Exercise	Non-Qualified Stock Option (Right to Buy)	822	$0.00	$0.00
Exercise	Non-Qualified Stock Option (Right to Buy)	1,113	$0.00	$0.00
Exercise	Incentive Stock Option (Right to Buy)	188	$0.00	$0.00
Exercise	Non-Qualified Stock Option (Right to Buy)	823	$0.00	$0.00
Exercise	Common Stock	188	$44.36	$8K
Exercise	Common Stock	822	$44.36	$36K
Exercise	Common Stock	1,113	$48.51	$54K
Exercise	Common Stock	188	$44.36	$8K
Exercise	Common Stock	823	$44.36	$37K
Sale	Common Stock	3,134	$85.00	$266K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 91,985 contracts (Direct); Incentive Stock Option (Right to Buy) — 8,640 contracts (Direct); Common Stock — 63,221 shares (Direct)

Key Figures

Shares sold: 3,134 shares Sale price: $85.00 per share Options exercised (shares): 3,134 shares +4 more

7 metrics

Shares sold 3,134 shares Open-market sale of common stock on June 29, 2026

Sale price $85.00 per share Price for 3,134 common shares sold

Options exercised (shares) 3,134 shares Total shares acquired via option exercises (code M)

Option strike price $44.36 per share Exercise price on several option transactions

Option strike price $48.51 per share Exercise price on one option transaction

Option exercise count 5 transactions Number of derivative exercises reported (code M)

Net buy/sell direction net-sell of 3,134 shares Transaction summary netBuySellDirection and netBuySellShares

Key Terms

open-market sale, Non-Qualified Stock Option (Right to Buy), Incentive Stock Option (Right to Buy), derivative exercise/conversion, +1 more

5 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Non-Qualified Stock Option (Right to Buy) financial

"security_title": "Non-Qualified Stock Option (Right to Buy)""

Incentive Stock Option (Right to Buy) financial

"security_title": "Incentive Stock Option (Right to Buy)""

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

transaction_code "M" financial

"transaction_code": "M""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cytokinetics (CYTK) CFO Sung Lee report in this Form 4?

Cytokinetics CFO Sung Lee reported exercising stock options for 3,134 shares and selling 3,134 common shares. The trades reflect routine management of equity compensation, combining derivative exercises with an open-market sale at a higher market price.

How many Cytokinetics (CYTK) shares did the CFO sell and at what price?

Sung Lee sold 3,134 shares of Cytokinetics common stock at $85.00 per share. This open-market sale was disclosed as a non-derivative transaction, separate from his option exercises reported for the same date.

What stock options did the Cytokinetics CFO exercise in this filing?

The CFO exercised options covering a total of 3,134 shares of Cytokinetics common stock. These options had exercise prices of $44.36 and $48.51 per share and were reported across several transactions on June 29, 2026.

Does this Cytokinetics Form 4 show new option exercises or just sales?

The Form 4 shows both new option exercises and a sale. Sung Lee exercised options for 3,134 shares at strike prices of $44.36 and $48.51, then sold 3,134 common shares in an open-market transaction at $85.00 per share.

Is the Cytokinetics CFO’s transaction mainly a sale or an option exercise?

The activity combines option exercises and a sale. Sung Lee exercised options to acquire 3,134 shares and then sold 3,134 shares in the open market, a common pattern for monetizing equity compensation while adjusting overall exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/29/2026 - 05:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Sung

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/29/2026		M		188	A	$44.36	63,409	D
Common Stock	06/29/2026		M		822	A	$44.36	64,231	D
Common Stock	06/29/2026		M		1,113	A	$48.51	65,344	D
Common Stock	06/29/2026		M		188	A	$44.36	65,532	D
Common Stock	06/29/2026		M		823	A	$44.36	66,355	D
Common Stock	06/29/2026		S		3,134	D	$85	63,221	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Incentive Stock Option (Right to Buy)	$44.36	06/29/2026		M			188	04/14/2025	03/13/2035	Common Stock	188	$0	8,828	D
Non-Qualified Stock Option (Right to Buy)	$44.36	06/29/2026		M			822	04/14/2025	03/13/2035	Common Stock	822	$0	40,504	D
Non-Qualified Stock Option (Right to Buy)	$48.51	06/29/2026		M			1,113	06/02/2025	05/30/2034	Common Stock	1,113	$0	52,304	D
Incentive Stock Option (Right to Buy)	$44.36	06/29/2026		M			188	04/14/2025	03/13/2035	Common Stock	188	$0	8,640	D
Non-Qualified Stock Option (Right to Buy)	$44.36	06/29/2026		M			823	04/14/2025	03/13/2035	Common Stock	823	$0	39,681	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Lee	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR